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As an obligate intracellular parasite, Kaposi sarcoma-associated herpesvirus (KSHV) relies
on the host cell machinery to meet its needs for survival, viral replication, production,
and dissemination of progeny virions. KSHV is a gammaherpesvirus that is associated
with three different malignancies: Kaposi sarcoma (KS), and two B cell lymphoproliferative
disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease. KSHV
viral proteins modulate the cellular phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian
target of rapamycin (mTOR) signaling pathway, which is a ubiquitous pathway that also
controls B lymphocyte proliferation and development. We review the mechanisms by which
KSHV manipulates the PI3K/AKT/mTOR pathway, with a specific focus on B cells.
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INTRODUCTION
Kaposi sarcoma-associated herpesvirus (KSHV; also known as
human herpesvirus 8) is a human gammaherpesvirus that was
discovered in Kaposi’s sarcoma (KS) biopsies in 1994 (Chang
et al., 1994). Following this seminal discovery, KSHV has been
found in all forms of KS, including KS associated with AIDS
patients, as well as HIV-negative and transplant-associated KS.
In addition to KS, which is a vascular endotheliosarcoma, KSHV
is also tightly associated with two lymphoproliferative disor-
ders: primary effusion lymphoma (PEL; Cesarman et al., 1995)
and the plasmablastic variant of multicentric Castleman’s dis-
ease (MCD; Gessain et al., 1996), both arising from infection of
B cells. Owing to the association with these three cancers, KSHV
has been extensively studied, and the results of these studies have
revealed fascinating mechanisms by which this oncogenic her-
pesvirus alters the infected cell in order to promote transformation
and tumorigenesis.
B LYMPHOCYTE DEVELOPMENT
B and T cells descend from a common lymphoid progenitor cell,
itself derived from a hematopoietic stem cell precursor. In humans,
B cell development occurs in the bone marrow, where the earli-
est progenitor (or pre-pro) B cell expresses germline heavy- and
light-chain immunoglobulin genes (Murphy et al., 2008). As the B
cell matures, movement along the bone marrow and interaction
with stromal cells leads to maturation. D-J gene rearrangement
occurs in early pro-B cells, and continues to V-DJ rearrange-
ment in the late pro-B cell. These gene rearrangements create a
unique variable domain in the immunoglobulin. Allelic exclu-
sion is enforced by the pre-B cell receptor, whereby only one
allele encoding the rearranged heavy chain is expressed, thereby
ensuring that each B cell has specificity for a single antigen (Mur-
phy et al., 2008). Many rounds of cell division occur during the
transition of pro-B cells to the pre-B cell stage, leading to the for-
mation of numerous small pre-B cells with a specific rearranged μ
heavy-chain gene. Pre-B cells undergo light-chain gene rearrange-
ment, which is also accompanied by allelic exclusion. Since these
pre-B cells now produce both heavy- and light-chain proteins, they
are classified as immature B cells, and bear intact IgM molecules
on their cell surface (Murphy et al., 2008). For a review describing
normal B cell development, please see Montecino-Rodriguez and
Dorshkind (2012).
In addition to allelic exclusion, isotype exclusion also occurs in
immature B cells, wherein the immature B cell expresses only one
light chain (either λ or κ; Murphy et al., 2008). In humans, because
the κ gene rearranges prior to the λ gene, many more mature B cells
express the κ light chain rather than λ. The average distribution
of κ to λ-bearing B cells in humans is approximately 65:35%,
and aberration from this ratio is indicative of lymphoproliferative
disorders, reflecting dominance of one clone (Murphy et al., 2008).
PATHOPHYSIOLOGY OF KSHV-ASSOCIATED B CELL
MALIGNANCIES
PRIMARY EFFUSION LYMPHOMA
Primary effusion lymphoma mainly afflicts HIV-infected patients,
and occurs in body cavities such as the peritoneal, pleural,
and pericardial cavities (Green et al., 1995; Nador et al., 1996).
Some KSHV-positive lymphomas can also present as extranodal
solid masses, which may subsequently develop into an effusion.
Cells have an immunoblastic appearance with a high mitotic
index. KSHV-positive solid lymphomas represent an extracav-
itary variant of PEL (Arvanitakis et al., 1996). In PEL, every
tumor cell expresses between 50 and 150 copies of the KSHV
genome. The genome is found as an episome tethered to the
host cell chromosome by the virus-encoded latency-associated
nuclear antigen (LANA) protein (Ballestas et al., 1999; Cotter
and Robertson, 1999; Schwam et al., 2000; Garber et al., 2001).
Some PEL are co-infected with Epstein–Barr virus (EBV), another
lymphotropic gammaherpesvirus (Cesarman et al., 1996; Nador
et al., 1996).
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Patients with PEL present with lymphomatous effusions within
body cavities, in the absence of a solid tumor mass (Nador et al.,
1996; Ambinder and Cesarman, 2007). Cells contained within the
effusions are large, with abundant cytoplasm, and display mor-
phological aspects common to both large-cell immunoblastic and
anaplastic large cell lymphoma (Nador et al., 1996). Analysis of
Ig rearrangements suggests that PEL arises from clonal expansion
of an infected B cell (Green et al., 1995). PEL express syndecan
1/CD138, which is a plasma cell surface marker, in addition to
CD45 (Gaidano et al., 1997).
Although most PEL cell lines do not have translocations and
mutations e.g., c-myc and p53, many PEL possess numerous
genetic aberrations (Luan et al., 2010). Sophisticated compara-
tive genome hybridizations (CGH) studies reveal extensive copy
number aberrations comprising predominantly of gains and
amplifications. Two genes, SELPLG and CORO1C were found to
be the targets of amplification at chromosome 12q24.11. SELPLG
encodes a membrane-bound glycoprotein that binds to P, E, and
L-selectins, and is important for leukocyte recruitment to sites
of inflammation (Laszik et al., 1996). CORO1C is a member of
the coronin gene family that regulates actin-dependent processes
such as motility and vesicle trafficking, and whose expression
is associated with enhanced invasion and metastatic capability
(Roadcap et al., 2008). Deletions of the two fragile site tumor sup-
pressors, WWOX and FHIT, were also recently reported in PEL
(Roy et al., 2011).
MULTICENTRIC CASTLEMAN’S DISEASE
Multicentric Castleman’s disease, an atypical lymphoproliferative
disorder, is divided into the hyaline vascular type, and the plas-
mablastic type. KSHV is associated with the plasma cell variant
of MCD, which is multicentric in that several lymph nodes and
the spleen are involved in disease. In the context of HIV infection,
MCD is systemic, aggressive, and is associated with high fatality.
KSHV genomes are detected in almost all HIV+ MCD cases, and
∼50% of non-HIV+ cases of MCD (Soulier et al., 1995; Dupin
et al., 2000). AIDS patients diagnosed with MCD suffer sustained
fevers, weight loss, lymphadenopathy, and hepatosplenomegaly
(Du et al., 2001). MCD frequently progresses to lymphoma
or KS.
Multicentric Castleman’s disease is localized to the marginal
zone of lymph nodes and the spleen. The germinal centers resem-
ble follicular hyperplasia, and the mantle zone is generally intact
and surrounded by mature KSHV-infected plasmablasts (Dupin
et al., 1999; Katano et al., 2000; Parravicini et al., 2000). MCD cells
resemble plasmablast or pre-plasma cells (Jenner et al., 2003). All
KSHV-infected plasmablasts within the lesion exclusively express
theλ light chain of IgM (Du et al.,2001), and the presence of λ light
chains and absence of CD138 on MCD cells further suggests they
originate from the infection of a less differentiated B cell (Hassman
et al., 2011). Lymph nodes involved in MCD are characterized by
germinal center expansion and vascular endothelial proliferation.
MCD is characterized by elevated serum interleukin (IL)-6 levels
in the patient (Yoshizaki et al., 1989). These elevated IL-6 levels,
partially augmented by virally encoded IL-6 (vIL-6), create an
inflammatory microenvironment which significantly contributes
to the pathophysiology of MCD.
KSHV ALTERS NORMAL B CELL PROLIFERATION AND
DIFFERENTIATION, LEADING TO LYMPHOPROLIFERATIVE
DISORDERS
Both MCD and PEL are associated with infection of a pre-
terminally differentiated plasma cell. Gene expression arrays
indicate that PEL have a plasma cell expression profile, and
enhanced expression of genes involved in inflammation, adhe-
sion, and invasion (Jenner et al., 2003), likely contributing to their
malignant phenotype. MCD is characterized by the polyclonal
expansion of KSHV-infected plasmablasts that exclusively express
the λ light chain. No functional significance exists in whether a
plasmablast bears either λ or κ, as the isotype exclusion is purely
a function of order of light chain gene rearrangement.
It was unknown whether KSHV preferentially infected λ light-
chain bearing B cells due to an inherent, yet unknown survival
advantage to the virus/infected cell, or whether KSHV infection of
a more undifferentiated cell (prior to light chain rearrangement)
drove the expansion of λ-expressing B cells.
Hassman et al. (2011) attempted to address this question in a
recent study in which they infected ex vivo suspensions of human
tonsillar cells with purified KSHV. Despite the presence of various
cell types, KSHV infection was shown to preferentially occur in
B cells, as evidenced by LANA+ staining. The tonsillar cultures
contained both κ- and λ-expressing B cells, however, all LANA+
staining was observed within the λ subset. Furthermore, infection
with KSHV enhanced the proliferation of this IgMλ subset, which
was further augmented by treatment with IL-6. KSHV-positive
cells mirrored phenotypic characteristics of MCD cells, such as
blasting morphology and increased expression of IgMλ, CD27,
Ki67, and IL-6R.
This study also suggested that rather than naïve B cells, KSHV
preferentially infects IgM memory B cells, resident within sub-
epithelial regions of the tonsil and spleen. During plasmablast
differentiation, IgM memory B cells acquire phenotypic markers
such as Ki67+, IgM+, and CD27+, similar to MCD. This model
is concordant with molecular and seroepidemiological data sug-
gesting that the primary mode of KSHV transmission is via saliva
(Vieira et al., 1997).
Plasmablast differentiation, including that of IgM memory
B cells, can result from NF-κB activation, a signaling event
that occurs during KSHV infection, and also during latency.
The viral FADD-like IL-1β-converting enzyme (FLICE/caspase-
8) inhibitory protein (vFLIP) activates NF-κB signaling in latently
infected cells by associating with the IκB kinase (IKK) complex,
and driving degradation of IκBα, and thus, NF-κB translocation
into the nucleus. A consequence of NF-κB signaling is the promo-
tion of cell survival and proliferation pathways. Ballon et al. (2011)
constructed an inducible CD19- or Cγ1-driven conditional vFLIP
knock-in mouse, which targeted vFLIP expression to various stages
of B cell development. vFLIP expression in B cells was found to
prevent germinal center development, Ig class switching, and affin-
ity maturation; vFLIP expression resulted in splenomegaly in the
mice. Although transgenic mice did not recapitulate phenotypes
of PEL, B cells mimicked an MCD phenotype, with expansion
of IgM λ plasmablasts, concordant with the findings of Hassman
et al. (2011), indicating that vFLIP leads to expansion of the IgMλ
subset upon KSHV infection. Moreover, impaired GC formation
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and class switch recombination resulting from vFLIP expression
suggests that inhibition of the adaptive response is a means of
escaping immune surveillance.
Interestingly, 20-month old vFLIP-expressing mice developed
B cell-derived histiocytic/dendritic cell (DC) sarcoma. This find-
ing is important as it underscores the ability of vFLIP to either
reprogram or transdifferentiate the infected lymphocytes or the
bystander cells in a paracrine manner, into other cell types. These
findings also demonstrate the inherent plasticity of B lymphocytes
(Cobaleda and Busslinger, 2008).
The collective body of research suggests that KSHV viral onco-
genesis is mediated by expression of both latent and lytic viral
gene products. Viral latent proteins are expressed in every tumor
cell, whereas lytic proteins are expressed in a small percentage
of tumor cells undergoing reactivation, and are thought to pro-
mote cell proliferation in an autocrine or paracrine manner. KSHV
can infect a wide range of cell types in vitro and in vivo includ-
ing monocytes, plasmacytoid DCs, fibroblasts, keratinocytes, B
lymphocytes, endothelial, and epithelial cells (Kliche et al., 1998;
Renne et al., 1998; Lagunoff et al., 2002; Akula et al., 2003; Inoue
et al., 2003; Krishnan et al., 2004; Naranatt et al., 2004; Kaleeba
and Berger, 2006a,b; Rappocciolo et al., 2006, 2008; Jarousse
et al., 2008; Greene and Gao, 2009; Hassman et al., 2011; West
et al., 2011; West and Damania, 2008). To guarantee successful
replication within these distinct cell types, KSHV encodes an
arsenal of viral proteins that are capable of modifying the host
cell environment, either directly or indirectly, with the outcome
being beneficial for the virus. Modulation of host cell path-
ways includes evasion of both immunity as well as apoptosis,
induction of cell proliferation, and the promotion of cellular
metabolism, macromolecular synthesis, and protein translation.
One way KSHV accomplishes these alterations is by targeting
the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian tar-
get of rapamycin (PI3K/AKT/mTOR) pathway. Similar to KSHV,
many DNA viruses encode one or more viral proteins that either
activate or inactivate various nodes of this pathway (Buchkovich
et al., 2008).
KSHV LIFE CYCLE
Kaposi sarcoma-associated herpesvirus establishes lifelong latency
within the host, punctuated with sporadic bouts of reactivation
and lytic replication. During latency, the KSHV genome exists as
a circular, extra-chromosomal viral genome (episome), with min-
imal expression of a subset of latent viral proteins: K12/Kaposin,
K13/vFLIP, ORF72/vCyclin, ORF73/LANA, vIL-6, and K1 (Wen
and Damania, 2010b). In contrast, during the lytic replication
phase, most of the viral genome is expressed and viral replica-
tion is followed by viral assembly, egress, and dissemination. The
lytic switch protein replication and transcription activator (RTA)
governs KSHV reactivation (Sun et al., 1998; Lukac et al., 1999).
Chemicals such as phorbol esters, sodium butyrate, and histone
deacetylase inhibitors reactivate the virus by activating the RTA
promoter (Yu et al., 1999), and thus are useful for studying the viral
life cycle. Hormones (norepinephrine and epinephrine), cytokines
such as interferon-γ, oncostatin M, and hepatocyte growth factor
reactivate KSHV, as does the hypoxic microenvironment typical of
solid tumors and serous cavities, thus stimulating the expression
of viral proteins that are beneficial to the host cell (Chang et al.,
2000; Mercader et al., 2000). Terminal differentiation of B cells,
resulting from expression of X-box binding protein 1 (XBP-1) can
also activate the RTA promoter, inextricably linking virion produc-
tion to the host cell life cycle (Wilson et al., 2007; Yu et al., 2007).
Furthermore, stimulation of Toll-like receptors (TLRs) 7 and 8
by microbes can also reactivate KSHV from latently infected cells
(Gregory et al., 2009); stimulation of these pattern recognition
receptors generates an anti-viral state, and expressed lytic proteins
have many functions which antagonize the host immune system.
Kaposi sarcoma-associated herpesvirus reactivation from
latency significantly alters the physiology of the infected cell. Viral
replication can reveal viral nucleic acid or peptide motifs that can
activate host immune surveillance pathways. Viral replication also
increases the demand for macromolecules such as nucleotides and
amino acids to synthesize progeny virions. Cellular energy pools
are substantially depleted in order to fuel the increased biosyn-
thetic rates associated with viral replication. The combined effect
of enhanced biosynthetic rates and unfulfilled energy demands is
the activation of cellular stress responses, resulting in cell cycle
arrest or apoptosis, in an attempt to resolve these deficits. To cir-
cumvent activation of stress responses, lytic proteins efficiently
block cell death pathways, and maintain the host cell in a constant
state of proliferation. Moreover, many lytic and latent proteins co-
opt cellular signaling pathways, which sustain proliferation, block
cell death, and enhance cellular metabolism, in order to main-
tain latent virus or facilitate lytic replication and dissemination
of KSHV. One such pathway is the pleiotropic PI3K/AKT/mTOR
pathway, which governs many cellular processes.
THE PI3K/AKT/mTOR SIGNALING PATHWAY
The following brief introduction describes the various effectors of
PI3K/AKT/mTOR signaling, and relates their activation to distinct
physiological outcomes for the cell. While no means exhaustive,
this description provides a primer for subsequent sections, which
describe KSHV’s interaction with this pathway. For recent reviews
describing up-to-date targets of PI3K/AKT/mTOR signaling, their
regulation, and relevance to malignancies, please refer to Bunney
and Katan (2010), Hsieh et al. (2011), Zoncu et al. (2011), and De
Luca et al. (2012).
The PI3K are lipid kinases that phosphorylate the 3′-hydroxyl of
the inositol ring of phosphoinositide, a component of the interior
side of eukaryotic cell membranes (Engelman et al., 2006). Phos-
phoinositides help form membrane cell signaling complexes and
are essential for intracellular trafficking. PI3K are divided into four
classes, IA, IB, II, and III, all of which have differing substrate speci-
ficities and modes of regulation. Class IA and IB PI3K catalyze the
phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2)
at the 3′ carbon on the inositol ring into phosphatidylinositol-
3,4,5-triphosphate (PIP3). PI(3,4,5)P3 production by PI3K allows
for pleckstrin homology (PH)-domain containing proteins to
localize to the plasma membrane (Engelman et al., 2006). PIP3
also functions as a cellular second messenger capable of control-
ling cell shape, survival, proliferation, growth, and motility. Class
I PI3Ks are heterodimeric proteins comprising a regulatory sub-
unit and a catalytic subunit. The regulatory subunits are p85α,
p85β, p55α, p55γ and p50α (Engelman et al., 2006). The catalytic
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subunits are comprised of one of four isoforms: p110α, p110β,
p110δ and p110γ. Most mammalian tissues widely express p110α,
β, and γ catalytic subunits, whereas p110δ is restricted to lym-
phocytes (Donahue and Fruman, 2004). Phosphatase and tensin
homology (PTEN) is a phosphatase that catalyzes dephosphory-
lation of the 3′ carbon on the inositol of PI(3,4,5)P3 back to PIP2
(Cantley and Neel, 1999). PTEN is one of the most frequently
lost tumor suppressors in various cancers. Mutations or dele-
tions in PTEN cause hyperactivation of PI3K signaling, leading
to increased cell proliferation as well as evasion of apoptosis. AKT
is a PH-domain-containing protein that plays a central role in
varied cellular processes such as glucose metabolism, evasion of
apoptosis, and promotion of cell proliferation, transcription and
cell migration (Manning and Cantley, 2007). AKT can also stim-
ulate protein synthesis via activation of mTOR (discussed below;
Hsieh et al., 2011). Once AKT is localized to the cell membrane
through its PH-domain, it is phosphorylated on Threonine308
by phosphoinositide-dependent kinase 1 (PDK1), and serine473
through the mTORC2 complex (Lawlor and Alessi, 2001), both
of which are activating modifications. AKT has several different
effectors, which control distinct biological processes, thus, AKT
activation has pleiotropic effects upon the cell. AKT inhibits cell
death by phosphorylation-mediated inactivation of pro-apoptotic
factors Bad, Caspase-9, and the FOXO group of transcription fac-
tors (Cross et al., 1995; Datta et al., 1997; del Peso et al., 1997;
Cardone et al., 1998). Phosphorylation of the FOXO transcrip-
tion factors sequesters them within the cytoplasm, thus preventing
them from transcriptionally activating target pro-apoptotic genes
such as Fas ligand and Bim.
AKT regulates the cell cycle by phosphorylating and inactivat-
ing key regulators of cell cycle progression. For instance, AKT
promotes the transcriptional activation of c-Myc and cyclin D1
genes (Gera et al., 2004), and interacts with two regulators of the
cell cycle, p27 and p21 (Zhou et al., 2001; Shin et al., 2002). Main-
taining a quiescent state requires high intracellular p27 levels, and
PI3K activation was shown to reduce the cellular reserves of p27
(Sun et al., 1999). AKT phosphorylates the p53-induced protein
p21, a negative regulator of cell cycle progression (Zhou et al.,
2001). The net result of these inhibitory phosphorylation events
is the maintenance of cell cycle progression and the de-regulation
of cellular checkpoint signaling.
AKT also activates the non-canonical branch of the NF-κB
family of transcription factors. NF-κB regulates many aspects of
innate and adaptive immunity and cell survival. NF-κB is nor-
mally sequestered in the cytoplasm by inhibitory proteins such as
inhibitor of κB (IκBα), which is degraded following phosphoryla-
tion by the upstream IKK complex, comprised of IKKα and IKKβ.
IκBα is a direct target of IKKβ, that when degraded, releases NF-
κB p65 thus activating genes involved in innate immune responses
IKKα activates non-canonical NF-κB, leading to formation of p52
which activates genes involved in adaptive immunity (Verma et al.,
1995; Ghosh et al., 1998; Karin and Ben-Neriah, 2000), and AKT
regulates non-canonical NF-κB p52 processing by increasing the
activity of IKKα (Gustin et al., 2006). Studies using constitutively
active AKT demonstrated elevated p52 transcriptional activity.
Non-canonical NF-κB activity was severely inhibited by using
PI3K inhibitors, kinase-dead AKT or cells lacking AKT isoforms 1
or 2 (Gustin et al., 2006; Comb et al., 2012). Thus, AKT modulates
both cell survival and regulation of adaptive immune responses.
de Oliveira et al. (2010) provide an excellent review of the role of
NF-κB signaling with regard to KSHV infection.
The serine/threonine kinase mTOR is a downstream target of
PI3K/AKT signaling. In addition to being activated by essential
signaling pathways such as PI3K and MAPK, mTOR is activated
by a wide range of cellular stimuli such as growth factors, stress
signals, and nutrient, energy, and amino acid abundance. mTOR
activity is negatively regulated by the tuberous sclerosis com-
plex (TSC), comprised of TSC1 and TSC2. TSC2 is an AKT
target, and when phosphorylated, inhibits Rheb, also a nega-
tive regulator of mTOR (Manning and Cantley, 2007). mTOR
exists in two distinct multiprotein signaling complexes, mTORC1
and mTORC2, which have differing sensitivities to the macrolide
rapamycin; mTORC1 is sensitive, whereas mTORC2 is insensitive.
mTORC1 regulates protein translation, cell size regulation, intra-
cellular transport, metabolism, and lipid biogenesis. mTORC1
phosphorylates S6K1 and 4EBP1, which are two proteins critical
for translation of eukaryotic capped mRNAs. S6K1 phosphorylates
the S6 ribosome, thus stimulating protein synthesis. Unphos-
phorylated 4EBP1 tightly binds and represses the eukaryotic
initiation factor 4E (eIF4E); hyperphosphorylated 4EBP1 releases
eIF4E, thereby enabling cap-dependent translation (Gingras et al.,
1999). mTOR has a wide plethora of other targets, for example
ULK1 which regulates autophagy (Zoncu et al., 2011). Because
protein translation is central to both cancer growth and viral
persistence, mTOR is a very important signaling protein. The
rapamycin-insensitive mTORC2 complex regulates cell survival
and cytoskeleton dynamics. mTORC2 activates AKT, thereby para-
doxically activating AKT/mTOR signaling even upon rapamycin
treatment, demonstrating a feedback activation loop (Sarbassov
et al., 2005).
Solid tumors are characterized by hypoxic microenvironments,
therefore, de novo angiogenesis as well as remodeling existing
blood vessels is essential to provide the rapidly growing cells with
nutrients and oxygen. The viscosity and shear forces of blood
against the walls of blood vessels govern the enzymatic activity
of endothelial cell-expressed NOS (eNOS), and consequently, the
continual synthesis and release of nitric oxide (NO). In endothe-
lial cells, AKT is activated in a PI3K-dependent manner, both
by shear forces and VEGF (vascular endothelial growth factor),
which collectively activate eNOS (Dimmeler et al., 1999). NO has
pleiotropic functions ranging from angiogenesis, remodeling of
the vasculature, and the control of blood vessel tone (Thomas
et al., 2008).
The AKT/mTOR axis is a critical regulator of cellular
metabolism. Activated AKT stimulates glucose uptake by re-
localizing the GLUT1 glucose transporter, thus bringing glucose
into the cell for fueling various cellular processes (Wieman et al.,
2007). Activation of the mTORC1 complex promotes glycolytic
flux, up-regulates the pentose phosphate pathway, and stimu-
lates de novo lipogenesis, all of which contribute to metabolic
reprogramming essential for rapidly dividing cancer cells (Duvel
et al., 2010).
As mentioned above, hyperactivation of PI3K/AKT/mTOR sig-
naling is a characteristic of many malignancies (Kodaki et al., 1994;
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Samuels et al., 2004). Deregulated signaling may result from inac-
tivation of negative regulator phosphatases, e.g., TSC2 or PTEN,
or from mutations in catalytic domains of kinases, e.g., PIK3CA.
Although KSHV-infected PEL cells are not known to have acti-
vating mutations in any of these three kinases, PI3K/AKT/mTOR
signaling is highly up-regulated in these cells (Sin et al., 2007; Bhatt
et al., 2010). As we will discuss further, a variety of viral proteins
can activate this signaling pathway.
Proper PI3K/AKT/mTOR signaling is essential for the dif-
ferentiation and developmental program of normal T and B
lymphocytes, as well as other immune cells. PI3K is downstream
of numerous cytokine receptors – CD40, TLRs, and the BCR itself.
The current body of research suggests that PI3K signaling regu-
lates the development of bone marrow B cell precursors, as well as
the differentiation and development of B cell subsets (Hodson and
Turner, 2009; Srinivasan et al., 2009; Beer-Hammer et al., 2010).
Moreover, PI3K signaling also governs many aspects of activation
and proliferation of mature B cells. For an excellent review describ-
ing the PI3K pathway with regard to B cell development, please see
Donahue and Fruman (2004).
KSHV ACTIVATES PI3K SIGNALING DURING DE NOVO
INFECTION
Kaposi sarcoma-associated herpesvirus activates the PI3K sig-
naling pathway during viral infection. The widely expressed
proteoglycan heparan sulfate, α3β1 integrins, DC-SIGN, and xCT
are the primary receptors for KSHV, and their differential distri-
bution in various cell types contributes to the wide tropism of
KSHV (reviewed in Chandran, 2010). KSHV enters target cells by
endocytosis. Viral entry activates many cellular signaling pathways,
which does not require active viral replication, as demonstrated by
studies using UV-inactivated KSHV (Chandran, 2010). Viral lig-
ation of cell-surface integrins triggers the phosphorylation and
activation of focal adhesion kinase (FAK) in fibroblasts (Krish-
nan et al., 2006). FAK further activates downstream signaling
molecules including Src, Rho GTPases, Diaphanous 2, and PI3K
(Naranatt et al., 2003; Sharma-Walia et al., 2004, 2005; Veettil
et al., 2006; Raghu et al., 2007). In turn, these molecules further
activate their own downstream effectors such as Ezrin, pro-
tein kinase C (PKC), MEK, NF-κB, ERK-1/2 and p38 MAPKs,
and AKT.
Integrin-mediated tyrosine phosphorylation of FAK occurs
minutes after KSHV infection of fibroblasts (Chandran, 2010).
Reduced viral genomes and gene expression are observed in cells
lacking either FAK or Pyk2, a FAK family member, illustrating
their essential role in viral infection of target cells (Naranatt et al.,
2003; Krishnan et al., 2006). FAK and Pyk2 signaling converge
onto the Src kinase family, whose downstream effectors are PI3K
and Rho GTPases. FAK, Src, and PI3K are also phosphorylated fol-
lowing infection of THP-1 monocytes, as are NF-κB and ERK-1/2
(Kerur et al., 2010). PI3K activation is crucial for de novo infec-
tion due to its activation of various GTPases involved in actin
cytoskeleton remodeling, endosome formation, and vesicle traf-
ficking. These intracellular processes allow for viral entry and
delivery into the nuclear compartment. PI3K and Rho GTPase
activation collectively induces other Rho GTPase family mem-
bers, which precipitate the formation of subcellular structures
such as lamellipodia (through Rac), stress fibers (through RhoA),
and filopodia (through Cdc42; Krishnan et al., 2006). Further,
activation of the PI3K target, AKT, leads to the inhibition of pro-
apoptotic factors, thus protecting KSHV-infected cells from cell
death.
Activation of cellular signaling is imperative for successful viral
infection. The signaling nodes described above activate the pro-
cesses of vesicle formation, intracellular motility, and evasion of
cell death. Furthermore, transcription factors activated by these
signaling pathways also play a role in activation of the viral tran-
scription program, as well as induction of cellular proteins that
facilitate viral replication. Thus, the collective activation of these
intracellular signaling pathways creates an environment benefiting
the KSHV life cycle.
KSHV VIRAL PROTEINS THAT ACTIVATE PI3K/AKT/mTOR
SIGNALING
Currently, four of the approximately 100 genes and microR-
NAs encoded by KSHV are known to impinge upon the
PI3K/AKT/mTOR signaling pathway. They are K1, viral G protein-
coupled receptor (vGPCR), vIL-6, and ORF45. We will discuss the
mechanisms, extent, context and physiological relevance of each
of these proteins below.
K1
K1 is the first ORF encoded by KSHV, and is located at the extreme
left end of the viral genome. K1 is a transmembrane glycopro-
tein whose expression in rodent fibroblasts induces morphological
changes and the ability to grow in foci, indicating K1’s transforma-
tion capacity (Lee et al., 1998). Further, infection of T lymphocytes
with a recombinant herpesvirus Saimiri expressing K1 instead of
the oncoprotein, Saimiri transforming protein (STP), conferred
IL-2 independent growth, suggesting that K1 is also an oncopro-
tein (Lee et al., 1998). All KSHV-associated tumors express low
levels of K1 transcript, and K1 expression is highly up-regulated
early during lytic replication (Lagunoff and Ganem, 1997; Jen-
ner et al., 2001; Lee et al., 2003; Wang et al., 2006; Chandriani
et al., 2010). K1 transgenic mice display constitutively active NF-
κB and Oct-2 transcription factors, increase in expression of basic
fibroblast growth factor (bFGF), as well as up-regulated expres-
sion and activity of the Lyn tyrosine kinase (Prakash et al., 2002).
A physiological consequence of K1-mediated alteration of the cel-
lular transcription program is the development of tumors similar
to spindle-cell sarcomatoid tumor and malignant plasmablastic
lymphoma (Prakash et al., 2002).
Various studies describe the extent to which K1 also dereg-
ulates normal cellular signaling (Figure 1). The regulatory p85
subunit modulates PI3K activity, and tyrosine-phosphorylation
of p85 results in activation of PI3K (Cuevas et al., 2001). K1
expression leads to increased tyrosine phosphorylation of p85, in
addition to phosphorylation of Vav and Syk, thus activating signal-
ing networks downstream of these kinases, which have pleiotropic
effects on the cell (Lagunoff et al., 1999; Lee et al., 2003; Tomlinson
and Damania, 2004). Further, activation of transcription factors
downstream of these kinases, for example, NFAT, downstream of
Syk signaling, further augments deregulation of cellular signaling
and promotes cell survival.
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FIGURE 1 | Kaposi sarcoma-associated herpesvirus K1 activates PI3K/AKT/mTOR signaling thereby activating protein synthesis and survival
pathways, while inhibiting apoptotic pathways. Orange circles denote phosphorylation.
In B lymphocytes, ectopic K1 expression was found to activate
AKT signaling in two simultaneous ways: K1 expression induced
AKT phosphorylation on Thr308 and Ser473, and also inactiva-
tion of the negative regulator PTEN (Tomlinson and Damania,
2004). K1-mediated AKT activation induced the cytoplasmic
sequestration of the FOXO family of transcription factors, and
subsequent reduction of Fas ligand expression, thus conferring
a cell survival advantage to K1-expressing cells (Tomlinson and
Damania, 2004). K1 also stabilizes AKT through interaction with
the cellular chaperones heat shock protein 90 β (Hsp90β) and the
endoplasmic reticulum-associated Hsp40 (Erdj3/DnaJB11), (Wen
and Damania, 2010a), both of which are important for enhanc-
ing the signaling function of AKT (Sato et al., 2000; Gao et al.,
2003). Chaperone-mediated stabilization of AKT by K1 is essential
for sustained signaling, as their inhibition induced caspase-3-
dependent apoptosis in FasL-treated, K1-expressing cells (Wen
and Damania, 2010a).
K1’s cytoplasmic tail contains an immunoreceptor tyrosine-
based activation motif (ITAM; Lagunoff and Ganem, 1997; Lee
et al.,2003). ITAMs are essential for signal transduction in immune
cells, therefore are found on immunoreceptors, for example,
CD79α and β, subunits of the B cell receptor complex. Upon ligand
binding, the tyrosine residues on ITAMs are phosphorylated,
which allow for docking of SH2 domain-containing molecules
(Figure 1). Downstream transduction of the extracellular signal
induces calcium mobilization from the endoplasmic reticulum,
and activates the lymphocyte. K1 does not require ligand bind-
ing to induce signaling, and functions as a constitutively active
receptor (Asmuth et al., 2003). The K1 ITAM is closely conserved
across KSHV strains, indicating the importance of this motif for
K1 function (Zong et al., 1999, 2002). The constitutive activity of
the K1 ITAM activates a variety of downstream signaling pathways
that not only protect the infected cell, but also neighboring cells in
a paracrine fashion. Notably, K1 also activates PI3K/AKT/mTOR
signaling in endothelial cells (Wang et al., 2004, 2006). Compo-
nents of the K1 signalosome have been identified, and indicate
that the K1 ITAM interacts with a diverse set of cellular signaling
proteins (Lee et al., 2005). Overall, K1 interactions with cellular
proteins augments global cellular signal transduction, activation
of transcription facts such as NF-κB and AP-1, and induction of
inflammatory cytokines (Lee et al., 2005).
Interactions of the K1 N-terminal domain with the BCR com-
plex induces BCR sequestration within the endoplasmic reticulum
(Lee et al., 2000). Because normal BCR signaling can potentially
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induce apoptosis, BCR sequestration preempts this possibility,
thus conferring a long-term survival advantage to the infec-
ted cell.
K1 expression is up-regulated during viral reactivation from
latency. Lytic replication may induce pro-apoptotic signals result-
ing from immune detection of replicating KSHV. Viral replication
also places increased demands for energy and nutrients on the
cell (Munger et al., 2006), and induces a stress response that
can activate apoptosis. These collective pro-apoptotic signals can
be subverted by K1 expression (Tomlinson and Damania, 2004;
Wen and Damania, 2010a), thereby supporting productive lytic
replication and further dissemination of KSHV. Moreover, PI3K
activation can also re-start protein translation and metabolic pro-
grams, halted as a result of apoptotic signals, ensuring that raw
materials for production of progeny virions are plentiful.
KSHV vGPCR
Kaposi sarcoma-associated herpesvirus ORF74 encodes a vGPCR,
a seven-pass transmembrane protein homologous to the cellu-
lar IL-8 chemokine receptor (Cesarman et al., 1996). vGPCR is
a ligand-independent receptor expressed during the lytic cycle.
Genes expressed during lytic replication are potently transform-
ing, as they exert strong survival signals to prolong the life of the
host cell, which ultimately dies as a result of viral replication and
associated cellular stress. vGPCR has transforming properties; it
promotes focus formation in mouse NIH3T3 cells, and vGPCR-
expressing cells form tumors in nude mice (Bais et al., 1998).
Human umbilical vein endothelial cells (HUVECs) are immor-
talized by vGPCR expression, and also protected from apoptosis
induced by serum-starvation (Montaner et al., 2001). In various
mouse models, vGPCR expression leads to formation of vascu-
lar tumors and KS-like angioproliferative lesions, with cell surface
markers and circulating cytokine profiles resembling KS (Yang
et al., 2000; Guo et al., 2003; Montaner et al., 2003).
Being a constitutively active receptor protein, vGPCR can
function without the need for ligand binding (Rosenkilde et al.,
1999). However, vGPCR is capable of binding members of both
CXC and CC chemokine families (Sodhi et al., 2004). Some CXC
chemokines, such as GRO-α and IL-8, enhance vGPCR signaling
(Rosenkilde et al., 2000), whereas interferon γ-inducible 10-kDa
protein (IP-10/CXCL10) and stromal cell-derived factor 1 α (SDF-
1α) inhibit vGPCR signaling (Gershengorn et al., 1998). IL-8
is a major mediator of inflammation, and recruits neutrophils,
basophils, and T cells. IL-8 released during the immune response
to lytic KSHV replication may enhance the function of vGPCR in
lytically infected cells, thereby inducing an anti-apoptotic signal
to delay the death of the infected cell. More puzzling is why SDF-
1/CXCL12, a stimulator of B cell progenitor proliferation, inhibits
vGPCR activity (Gershengorn et al., 1998). However, since vGPCR
is primarily expressed during the lytic cycle, this might not have a
consequence for latently infected B cells.
KSHV vGPCR activates a plethora of cellular signaling
molecules as well as transcription factors, by means of which it pro-
motes transformation in endothelial, epithelial, and fibroblast cells
(Figure 2). vGPCR activates pathways such as PLC/PKC,Pyk2/Lyn,
ERK, p38, and JNK, downstream of which are transcription factors
that control many growth- and angiogenesis-promoting genes.
For example, HIF-1α activation resulting from vGPCR-dependent
p38 and MAPK signaling activates the VEGF promoter (Sodhi
et al., 2000). vGPCR also activates AP-1, NF-AT, and NF-κB tran-
scription factors, which in turn promote expression of a panoply
of pro-inflammatory cytokines, growth factors, and adhesion
molecules (Couty et al., 2001; Montaner et al., 2001; Schwarz and
Murphy, 2001; Pati et al., 2003). The vGPCR-mediated secretion
of such a wide array of factors may enhance proliferation and
survival in neighboring, uninfected cells in a paracrine manner
(Figure 3). Indeed, a recent report demonstrates that cytokines
secreted by a small number of vGPCR-positive tumor cells activate
signaling pathways in neighboring cells, converging on mTOR-
dependent VEGF up-regulation (Jham et al., 2011). Inhibiting
paracrine mTOR activity in non-expressing cells abrogated the
tumor-promoting activities of vGPCR-expressing cells in vivo. On
the other hand, vGPCR expression may directly induce transfor-
mation of the cell, due to up-regulated signaling resulting from the
same secreted factors. These two methods of transformation may
act in concert, rather than in isolation, leading to transformation
of both the infected and bystander cells.
PI3K/AKT/mTOR signaling is a common pathway downstream
of many growth factor and cytokine receptors. In particular, the
tissue-restricted γ isoform of PI3K is crucial for relaying vGPCR
signaling downstream to AKT/mTOR in endothelial cells (Martin
et al., 2011). Paracrine secretions resulting from vGPCR expression
activate PI3K/AKT/mTOR signaling (e.g., VEGF), and more-
over, vGPCR directly activates AKT in a PI3K-dependent manner
(Montaner et al., 2001).
vGPCR expression in the B cell neoplasms, PEL and MCD,
exhibits a distinct gene expression profile compared to endothe-
lial cells (Polson et al., 2002), and is also characterized by elevated
PI3K/AKT and ERK/p38 MAPK signaling. Ectopic vGPCR expres-
sion in B cells activates several transcription factors: AP-1, CREB,
NF-AT, and NF-κB, thereby promoting cell survival, although
the mechanisms of activation of these transcription factors differ
(Cannon et al., 2003).
As mentioned above, although capable of constitutive activ-
ity, vGPCR can also signal by coupling with cellular Gαq and
Gαi subunits (Cannon and Cesarman, 2004), further amplify-
ing PI3K/AKT signaling, as both Gαq and Gαi subunits signal
through this pathway (Murga et al., 1998). Additionally, vGPCR-
mediated activation of AP-1 and CREB (but not NF-κB and NFAT)
in B cells was found to be dependent on PI3K/AKT (Cannon and
Cesarman, 2004). vGPCR also activates endogenous Lyn tyrosine
kinase in a Gαi- and PI3K-dependent manner. Pharmacologic and
genetic ablation of Src family kinases abolished AP-1 and CREB
transcriptional activity, confirming that these transcription factors
are activated by vGPCR through a Gαi-PI3K/AKT-Src signaling
axis. Further, this study showed that Src inhibitors decreased
AKT phosphorylation in PEL, indicating that in B cells, Src may
be upstream rather than downstream of PI3K/AKT signaling,
suggestive of a positive feedback loop. Importantly, this study
revealed that NF-κB and NF-AT are not activated in a PI3K/AKT-
dependent manner in B cells (Cannon and Cesarman, 2004).
Subsequent studies indicated that the Ras-related small G protein
Rac1 may be required for NF-κB activation via vGPCR (Montaner
et al., 2004).
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FIGURE 2 | Kaposi sarcoma-associated herpesvirus vGPCR broadly activates PI3K and MAPK pathways, leading to increased production of cytokines
and growth factors, with a concurrent increase in cell proliferation, and inhibition of apoptotic pathways. Orange circles denote phosphorylation.
The previous paragraphs describe the extent to which vGPCR
activates cellular signaling. The lytically replicating, vGPCR-
expressing cell activates transcription factors and signaling entities
within the infected cell; induction of secreted factors further
amplifies signaling in neighboring cells, with the collective out-
come of enhanced proliferation and sustained survival (Figure 3).
VIRAL IL-6
Viral IL-6, encoded by ORF-K2, is a homolog of the human IL-
6 (hIL-6) cytokine, with 24.8% amino acid sequence similarity
and 49.7% sequence identity (Moore et al., 1996). Functionally,
vIL-6 is a faithful mimic of hIL-6, as vIL-6 secreted by KSHV-
infected B lymphocytes supports proliferation of B lymphocytes
and also hIL-6-dependent mouse myeloma cell lines, demonstrat-
ing its functional similarity (Moore et al., 1996; Neipel et al., 1997;
Nicholas et al., 1997). Most latently infected cells express low levels
of vIL-6, with up-regulated expression during lytic replication
(Cannon et al., 1999; Staskus et al., 1999; Parravicini et al., 2000;
Chandriani et al., 2010). Similar to its cellular counterpart, vIL-6
signaling activates the JAK/STAT, MAPK, and H7-sensitive path-
ways (Osborne et al., 1999). Although vIL-6 and hIL-6 have similar
sequence and function, their receptor usage is substantially differ-
ent. Cellular IL-6 requires two IL-6 receptor subunits: IL-6Rα
and gp130. However, vIL-6 is capable of signaling via only the
gp130 subunit (Molden et al., 1997). Thus, KSHV vIL-6 circum-
vents the requirement for a second receptor, thereby subverting
cellular checks against uncontrolled, exuberant signaling.
vIL-6 is implicated as a linchpin in the pathology of all KSHV-
associated malignancies, due to its angiogenic properties, as well
as potent proliferative and survival effects. vIL-6 is detected, in
increasing order, in KS, PEL, and MCD patients (Aoki et al., 2000,
2001). However, only a subset of cells express vIL-6 in KS tissue
(Cannon et al., 1999; Staskus et al., 1999; Parravicini et al., 2000),
suggesting that like vGPCR, vIL-6 effects are primarily paracrine,
activating proliferative signaling pathways in bystander cells. Simi-
larly, in MCD, vIL-6 is expressed in lymphoid cells in mantle zones,
and hIL-6 was detected in germinal centers (Cannon et al., 1999;
Staskus et al., 1999; Parravicini et al., 2000).
Injection of vIL-6-expressing NIH3T3 cells into athymic mice
led to tumor formation, hematopoiesis, and plasmacytosis, all of
which were absent in control mice. Tumors derived from vIL-
6-expressing cells were highly vascularized, and correlated with
elevated secreted VEGF (Aoki and Tosato, 1999). A recent report
of transgenic mice constitutively expressing vIL-6 describes ele-
vated serum vIL-6, increased levels of phospho-STAT3 levels in the
spleen and lymph nodes, and a manifestation of human MCD-like
symptoms (Suthaus et al., 2012). Importantly, when vIL-6 was
constitutively expressed in a mouse lacking endogenous hIL-6, no
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FIGURE 3 | Viral proteins enhance cell proliferation by autocrine and paracrine mechanisms. Viral and cellular cytokines and growth factors can activate
signaling pathways within the cell they are secreted from (autocrine), or on distant cells that may either be uninfected or latently infected with KSHV (paracrine).
RTK, receptor tyrosine kinase.
MCD-like symptoms were observed. These studies indicate that
vIL-6 and hIL-6 cooperate in the pathogenesis of MCD.
Lymphatic reprogramming resulting from KSHV infection of
endothelial cells also occurs via engagement of the gp130 receptor
(Morris et al., 2008). Specifically, gp130 receptor activation leads to
the activation of JAK2/STAT3 and PI3K/AKT pathways. Activated
AKT promotes the expression of Prox1, a lymphatic transcrip-
tion factor necessary for VEGFR-3 induction, and Prox1 itself is
known to potentiate the lymphatic reprogramming of endothelial
cells upon de novo KSHV infection (Hong et al., 2004). Further-
more, STAT3 amplifies this signaling cascade by activating gp130
receptor expression. Podoplanin, another marker of lymphatic
reprogramming, is also expressed following KSHV activation of
gp130. While not found to be necessary, vIL-6 is sufficient to
induce lymphatic reprogramming in endothelial cells infected
with KSHV (Morris et al., 2012). Thus, through gp130, vIL-6
can enhance lymphangiogenesis and lymphatic reprogramming
in both a paracrine and autocrine manner.
ORF45
ORF45 is an immediate early gene product that plays a crucial
role in lytic replication. ORF45 expression is induced upon entry
into the lytic cycle and subsequently increases as the life cycle
advances, with expression restricted to the cytoplasm. ORF45 is
incorporated into the KSHV virion (Zhu and Yuan, 2003), sug-
gesting that it may immediately influence the environment of the
de novo infected host cell, exemplified by the observation that
ORF45 acutely inhibits type 1 IFN induction upon infection.
ORF45 mediates the inhibition of innate immune responses by
sequestering the cellular transcription factor, interferon regulatory
factor-7 (IRF-7), to the cytoplasm (Zhu et al., 2002).
In addition to the modulation of cellular anti-viral responses,
ORF45 also exerts an effect upon the cellular signaling milieu.
Cellular MAPKs are activated during KSHV infection (Sharma-
Walia et al., 2005; Xie et al., 2005), and ORF45 interacts with two
important MAPK substrates RSK1 and RSK2, which are both p90
ribosomal S6 kinase (RSK) family members. RSK1 and 2 not only
phosphorylate ORF45, but their association further augments the
kinase activities of these two proteins (Kuang et al., 2008, 2009).
Another consequence of formation of the RSK/ERK/ORF45
complexes is phosphorylation of ribosomal protein S6, and eIF4B,
an important member of the complex that recruits ribosomes to
5′ capped mRNAs. Phosphorylated eIF4B complexes with eIF4A,
eIF4G, 4E-BP1, and 5′ capped mRNAs to recruit the 40S ribosome,
thereby initiating protein translation. Normally, S6 and eIF4B are
activated by p70 S6 kinase, itself regulated by upstream mTOR
signaling; eIF4B is also a target of the p90 S6 kinase, regulated
by MAPK signaling. However, ORF45 allows for eIF4B phospho-
rylation in an mTOR- and MAPK-independent manner. These
observations indicate that protein translation may occur upon
KSHV infection in an mTOR-independent manner. They also
demonstrate the existence of unique viral strategies to directly
enhance protein translation despite a situation within the host cell
that may potentially be inhibitory to protein translation.
KSHV-MEDIATED TRANSFORMATION AND THE HALLMARKS
OF CANCER
The hallmarks of cancer are a conceptual framework to understand
the multistep progression of cancer (Hanahan and Weinberg, 2000,
2011). The hallmarks of cancer take into account that neoplasms,
rather than being a singular, isolated entity, are a collection of
distinct cell types, comprised of tumor cells, tumor-associated
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stroma as well as normal, non-cancerous cells. These diverse
cell types cooperate to collectively confer hallmark capabilities,
which further enhance the development of a tumor microenvi-
ronment. Acquisition of one hallmark by a normal cell facilitates
the development of others, thus increasing the likelihood of cellu-
lar transformation. The classical hallmarks of cancer are sustained
proliferation signaling, evasion of growth suppression, replica-
tive immortality, induction of angiogenesis, evasion of cell death,
and invasion and metastasis. Three additional hallmarks have
also been recently proposed: deregulation of cellular energet-
ics, tumor-promoting inflammation, and avoidance of immune
recognition.
The endpoint of the productive KSHV life cycle is the produc-
tion of new virions that can subsequently infect new cells, and
begin another round of the viral life cycle. To successfully replicate
and generate progeny virions, KSHV must evade immune recogni-
tion during latency, and also counter antiviral and death-inducing
signaling during lytic replication. A plethora of viral proteins
successfully grant invisibility from immune recognition, and pro-
long the life of the infected cell by altering cellular signaling, as
described above.
SUSTAINED PROLIFERATIVE SIGNALING
Proliferation is a carefully controlled process in normal cells.
Uncontrolled growth would lead to nutrient scarcity as well as
overgrowth in the physical niche. KSHV encodes genes that
activate cellular proliferative pathways both in a paracrine and
autocrine fashion (Figure 3; Lagunoff et al., 1999; Lee et al., 2003;
Tomlinson and Damania, 2004). This hallmark is particularly evi-
dent in KS, as not all cells within the lesion are KSHV-positive;
expression of viral and cellular factors bestows neighboring cells
with enhanced proliferative capabilities. Sustained proliferation
results from growth factors binding to their cognate cell sur-
face receptors, and subsequent signaling that further promotes
expression of the same growth factors and receptors, in a positive
feedback loop.
EVASION OF GROWTH SUPPRESSION AND CELL DEATH
Powerful growth inhibitory programs are intrinsic to the host
cell to prevent uncontrolled proliferation. Hyperproliferation can
trigger cell senescence via activation of checkpoint signaling.
Alternatively, apoptosis may also result from aberrant oncogene
activation. Immune cells that detect virally infected cells may also
transduce apoptotic signals to facilitate viral clearance.
KSHV encodes several proteins to protect the infected cell from
these growth suppressive and cell death-inducing signals, dur-
ing latency and the lytic cycle. For example, vCyclin, a homolog
of cellular cyclin D, forces quiescent rodent cells to enter the S-
phase to overcome RB-mediated growth arrest induced by CDK
inhibitors (Swanton et al., 1997). In the same vein, cells supporting
lytic replication do not die prematurely despite increased cellular
stress, due to the presence of viral proteins that inhibit apop-
totic signaling. As described above, K1-dependent, AKT-mediated
sequestration of FOXO transcription factors and inactivation of
Bad can protect B cells from apoptosis (Tomlinson and Damania,
2004). Similarly, vFLIP expression also protects cells from apopto-
sis by up-regulating NF-κB transcription and pro-survival factors
(Sun et al., 2003; Matta and Chaudhary, 2004; Thurau et al., 2009).
In the context of the whole virus, KSHV-infected primary HUVEC
cells are more resistant to apoptotic stimuli such as etoposide, stau-
rosporine, and serum-starvation, compared to uninfected cells
(Wang and Damania, 2008). Thus, evasion of both cell death and
growth suppression by viral proteins expressed during latency and
the lytic cycle contribute to the development of KSHV-associated
cancers.
REPLICATIVE IMMORTALITY
Somatic cells within the body divide a finite number of times,
i.e., they have limited replicative potential. Upon reaching their
limit, normal cells senesce and cannot proliferate any further.
The number of cell divisions is governed in part by telomeres,
which are stretches of repetitive DNA at the ends of chromo-
somes that shorten after every cell division. However, cancer cells
can replicate indefinitely owing to activation of one of two path-
ways: activation of human telomerase (hTERT), or the activation
of an alternative (ALT) pathway, both of which lead to length-
ening of telomeres. KSHV LANA has been shown to increase
the expression of the catalytic subunit of telomerase, hTERT
by up-regulating its promoter, thereby contributing to replica-
tive immortality (Knight et al., 2001). Additionally, K1 expression
in primary HUVECs endows replicative immortality, primarily
through the ALT pathway (Wang et al., 2006).
INDUCTION OF ANGIOGENESIS
All cells, whether normal or cancerous, require a reliable blood
supply to provide nutrients and oxygen, and to eliminate car-
bon dioxide and metabolic waste products. Tumor cells promote
formation of vasculature by activating angiogenesis, as well as
remodeling of existing vasculature and sprouting new vessel
growth. Often, tumor-associated vessels are erratically branched,
aberrantly sized, excessively convoluted and structurally unsound,
all resulting from hyperactivated induction of angiogenic factors
(Baluk et al., 2005; Nagy et al., 2010). VEGF is a key media-
tor of angiogenesis, and its expression is governed by upstream
signaling pathways such as PI3K/AKT (Jiang and Liu, 2009).
Other inflammatory cytokines can also drive angiogenesis. KSHV
vGPCR induces VEGF and VEGF receptor 2 secretion in endothe-
lial cells (Bais et al., 2003). Moreover, K1 expression in epithelial
and endothelial cells also induces secretion of VEGF and the inva-
sion factor matrix metalloprotease-9 (MMP-9; discussed below),
as does KSHV infection of endothelial cells (Wang et al., 2004;
Wang and Damania, 2008).
INVASION AND METASTASIS
Invasion and metastasis is a multistep process that begins with local
invasion due to cancer cells exceeding their occupied niche, result-
ing from hyperproliferation. Cancer cells that weakly adhere to
neighboring cells easily escape and intravasate nearby blood vessels
and lymph nodes and travel to distal sites through vasculature and
lymphatics (Langley and Fidler, 2011). Some cells escape these ves-
sels and enter a new environment, often substantially different than
the first, forming micrometastases; in the final stage, these grow
into larger masses that colonize the new niche, generating metas-
tases (Langley and Fidler, 2011). Activation of a developmental
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regulatory program termed “epithelial–mesenchymal transition”
(EMT) bestows onto epithelial cells the ability to invade and
metastasize (Thiery, 2002; Mani et al., 2008). EMT includes a
transcriptional and signaling program, and a similar, “endothe-
lial to mesenchymal” (EndMT) transition occurs in the context of
KSHV infection (Cheng et al., 2011). vFLIP and vGPCR activate
the Notch signaling pathway, resulting in secretion of the mes-
enchymal marker membrane type-1 MMP (MT1-MMP), granting
invasive properties to KSHV-positive cells. Significantly, MT1-
MMP was found co-localized with LANA in KS biopsies. These
data suggest that the presence of heterogeneous cell types within
KS lesions can result from viral proteins driving EndMT within
infected cells, bestowing them with invasion capabilities, and the
creation of a microenvironment that benefits viral dissemination.
DEREGULATION OF CELLULAR ENERGETICS
Recent evidence suggests that the reprogramming of cellular ener-
getics and metabolism is an emerging hallmark of cancer (reviewed
in Hanahan and Weinberg, 2011). Fueling uncontrolled prolifer-
ation and cell division of tumor cells requires rewiring of normal
cellular energetics. Normal cells, in aerobic conditions, utilize
glucose to first generate pyruvate and ATP by glycolysis, and
subsequent mitochondrial oxidative phosphorylation (OXPHOS).
Anaerobic conditions result in a switch to glycolysis, which is rel-
atively inefficient and generates smaller quantities of ATP, which
may or may not be accompanied by reduced OXPHOS. Warburg
observed that cancer cells preferentially oxidize glucose by glycol-
ysis even in aerobic conditions, limiting their energy production;
this phenomenon is termed the Warburg effect, or aerobic glycol-
ysis (Warburg et al., 1924). The Warburg effect is an adaptation of
tumors growing in hypoxic conditions to generate ATP. KSHV
infection of endothelial cells induces the Warburg effect, and
glycolysis inhibition of latently infected cells leads to apoptosis
(Delgado et al., 2010). Moreover, we reported that in KSHV-
infected PEL, aerobic glycolysis fuels de novo lipid synthesis to
generate precursors for daughter cells, explaining the significance
of up-regulating an energetically unfavorable biochemical process
(Bhatt et al., 2012). This study also demonstrated that glycolysis
and fatty acid synthesis (FAS) occur in a PI3K/AKT-dependent
manner, providing a mechanism for metabolic reprogramming in
PEL. Further, PEL viability was found to be susceptible to FAS
inhibitors, revealing a new molecular therapeutic target.
IMMUNE EVASION
An ever-watchful immune system surveys the body for signs of
nascent neoplasms, and eliminates such cells. The ability to escape
immune surveillance is a frequent consequence of genetic instabil-
ity and aberrant signaling in tumors. KSHV-associated tumors are
even more adept at hiding from the immune system as viral protein
expression can subvert various aspects of the innate and adaptive
immune response. Viral proteins, e.g., KSHV vIRFs, K3, K5, etc.
inhibit immune signaling, protecting the infected cell from host
detection. For example, the K3 and K5 viral proteins can down-
regulate both class I and II major histocompatibility complexes
(MHC), enhancing the immunoevasion capabilities of infected
cells (Coscoy and Ganem, 2000; Ishido et al., 2000). The KSHV
vIRFs also contribute to immune evasion (reviewed in Jacobs and
Damania, 2011). As discussed in previous sections, apoptotic sig-
naling resulting from immune detection is also potently inhibited
by viral protein expression.
TUMOR-PROMOTING INFLAMMATORY MICROENVIRONMENT
Similar to non-viral tumors, KSHV-associated lesions are infil-
trated by a large number of immune cells. KSHV-associated
neoplasms are also characterized by elevated local and systemic
levels of inflammatory cytokines and chemokines, further aug-
mented by virally encoded cytokines such as vIL-6, vMIPs/vCCls,
and vOX2. KSHV infection up-regulates cyclooxygenase-2 (COX-
2), an enzyme that converts arachidonic acid into prostaglandins,
which are inflammation mediators (Sharma-Walia et al., 2010).
COX-2 is essential for survival of KSHV-infected cells, and viral
genome maintenance, both of which are susceptible to COX-2
pharmacological inhibitors. Creation of an inflammatory envi-
ronment is functionally significant, since it activates signaling in
surrounding tissues, and recruits readily infectable cell types to
facilitate viral dissemination.
EXPLOITING THE PI3K/AKT/mTOR PATHWAY TO TREAT
KSHV-ASSOCIATED MALIGNANCIES
Individual KSHV proteins can activate PI3K/AKT/mTOR signal-
ing in B cells and endothelial cells, and this pathway is important
for both lytic and latent phases of the KSHV life cycle. Additionally,
both KS and PEL display highly activated AKT and mTOR kinases
(Montaner et al., 2001; Uddin et al., 2005; Sin et al., 2007). Because
aberrant PI3K/AKT/mTOR signaling is a characteristic of almost
all human cancers, a plethora of small molecule inhibitors exist
that target various nodes of this pathway. These inhibitors include
allosteric inhibitors such as rapamycin and FK506, and also ATP-
competitive small molecule kinase inhibitors that usually target
the kinase activity of specific proteins.
Rapamycin is a macrolide that binds to FKBP12, a compo-
nent of the mTOR signaling complex (mTORC), thus making it
an allosteric inhibitor (Sawyers, 2003). Rapamycin is commonly
used as an oral immunosuppressant for solid organ transplant
recipients, as it inhibits the production and secretion of IL-2 in
T cells, thus blocking T cell proliferation. Moreover, rapamycin
blocks protein translation. Therefore, rapamycin and its deriva-
tive compounds called “rapalogs” are extensively studied for their
therapeutic benefit in a variety of human cancers, including those
associated with viral infection (Dittmer et al., 2012). Rapamycin
treatment resolved transplant-associated KS (Stallone et al., 2005),
a seminal finding that has prompted many other studies which
confirm that rapamycin is an effective anti-cancer drug for PEL
(Sin et al., 2007). Specifically, rapamycin is effective at halting
the proliferation of PEL in cell culture, and in a xenograft model
of PEL, rapamycin inhibits tumor formation and induces tumor
regression (Sin et al., 2007). One drawback of rapamycin therapy
is that it slows tumor growth (tumorstatic), rather than killing
tumor cells (tumortoxic). Therefore, single agent therapy with
rapamycin alone has limited benefit in a majority of cancers.
A class of AKT inhibitors called alkyl-lysophospholipids (e.g.,
miltefosine and perifosine) also inhibited PEL cell proliferation
both in vitro and in vivo (Bhatt et al., 2010). Moreover, NVP-
BEZ235, a dual inhibitor of both PI3K and mTOR kinases, is a
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potent inhibitor of PEL cell proliferation and tumor formation in
xenograft mouse models. NVP-BEZ235 treatment induced high
levels of apoptosis in PEL (Bhatt et al., 2010). Thus, it appears
that the PI3K/AKT/mTOR signaling pathway is essential for the
survival of both PEL and KS tumors. It is of critical importance
to evaluate whether long-term treatment with small molecule
inhibitors breeds resistance to pathway-focused inhibitors. Selec-
tive pressure resulting from these inhibitors could drive expression
of viral proteins that may contribute to resistance. Therefore in the
future, it will be important to investigate whether as yet unchar-
acterized KSHV proteins influence PI3K/AKT/mTOR signaling,
both in the context of latency and lytic viral replication.
CONCLUSION
Kaposi sarcoma-associated herpesvirus is an obligate intracellu-
lar parasite, and is a salient example of a successful pathogen.
Viral manipulation of cellular pathways enhances the synthesis and
secretion of growth factors and cytokines of both viral and cellu-
lar origin, which in turn support angiogenesis and proliferation.
These secreted growth factors and cytokines can also activate pro-
survival, proliferative, and angiogenic processes in uninfected or
latently infected cells (Figure 3). Thus, by manipulating cellular
signaling, KSHV viral proteins create an environment beneficial
for both lytic and latent phases of the viral life cycle. Given the
central role it plays in cell survival and proliferation, it comes
as no surprise that KSHV targets the PI3K/AKT/mTOR signal-
ing pathway at multiple nodes, in order to induce and sustain
a survival and proliferative signal that is advantageous for the
virus.
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